Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human

Леонова, Г Н; Павленко, Е. В.

doi:10.1016/j.vaccine.2009.02.069

Cited by 48 publications

(42 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Иммуно-генность вакцины ФСМЕ-Иммун ® по уровню специфических Примечание. Таблица адаптирована из работы [35].…”

Section: иммунологическая эффективность и безопасность вакцин для проunclassified

“…В ряде работ показано, что вакцины для профилактики КЭ обеспе-чивают перекрестную иммуногенность в отношении всех трех подтипов вируса [33][34][35]. Имеются данные о том, что вакцины на основе европейского подтипа формируют защитный имму-нитет не только в отношении гомологичного штамма вируса, но также и в отношении гетерологичных (дальневосточного и сибирского подтипов) [1].…”

Section: перекрестная защита вакцин для профилактики кэunclassified

See 1 more Smart Citation

Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

Козлова¹,

Хантимирова²,

Рукавишников³

et al. 2018

Biopreparaty. Profilaktika, diagnostika, lechenie

View full text Add to dashboard Cite

В статье приведен анализ эффективности и безопасности вакцин для профилактики клещевого энце-фалита (КЭ), разрешенных для применения на территории Российской Федерации. Показано, что ис-пользуемые в настоящее время вакцины КЭ отечественного и зарубежного производства обеспечивают высокую иммуногенность, безопасность и эпидемиологическую эффективность в регионах с массовым охватом вакцинацией. Все зарегистрированные вакцины соответствуют основным принципам взаимо-заменяемости по показаниям к применению с учетом возрастных ограничений, перечню медицинских противопоказаний, схемам вакцинации, составу вакцин, а также показателям безопасности, иммуноло-гической активности и эффективности. Своевременные меры специфической профилактики приводят к снижению заболеваемости КЭ в эндемичных регионах. This article provides a review on efficacy and safety of tick-borne encephalitis vaccines licensed in the Russian Federation. It highlights that both Russian and imported tick-borne encephalitis vaccines demonstrate high immunogenicity, safety and epidemiological effectiveness in regions with high vaccine coverage. All licensed tick-borne encephalitis vaccines meet interchangeability criteria in terms of indications for use (with due regard to age limits), medical contraindications, vaccination schedules, vaccine composition, as well as safety, immunological activity and efficacy parameters. Timely and specific prophylaxis help reduce the incidence of tick-borne encephalitis in endemic regions.

show abstract

Section: иммунологическая эффективность и безопасность вакцин для проunclassified

Section: перекрестная защита вакцин для профилактики кэunclassified

Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

Козлова¹,

Хантимирова²,

Рукавишников³

et al. 2018

Biopreparaty. Profilaktika, diagnostika, lechenie

View full text Add to dashboard Cite

show abstract

“…Chumakov Institute of Poliomyelitis and Viral Encephalitides (Moscow, Russia) and "EnceVir" manufactured by SPA "MicroGen" (Tomsk, Russia) [Vorobyova MS, 2007]. We have performed cohort and simultaneous study of immunologic effectiveness of the four vaccines against TBE in relation to several contemporary Far Eastern TBEV strains on 290 volunteers [Leonova GN & Pavlenko EV, 2009]. We evaluated immunologic activity of the vaccines against TBE according to the intensity of antibody response one and two years later after full course of immunization with the vaccines.…”

Section: Comparative Evaluation Of Immunologic Activity Of Vaccines Amentioning

confidence: 99%

“…We have concluded that all studied vaccines are able to induce neutralizing antibodies against contemporary TBEV strains [ Leonova GN & Pavlenko EV, 2009]. Levels of seroconversion for the vaccine "FSME-IMMUN-Inject" (Austria) were 88.2% in the year after full course of immunization and 78.1% of cases -two years later, "Encepur® Adults" (Germany) -100% and 100%, the vaccine manufactured by IPVE RAMS (Moscow) -100% and 94.1%, "EnceVir" (Tomsk) -88.2% and 83.9%, and during the combined vaccination -100% and 92.7% of cases, respectively.…”

Section: Comparative Evaluation Of Immunologic Activity Of Vaccines Amentioning

confidence: 99%

“…On the other hand, new genetically different variants within the Far Eastern subtype of TBEV were found. They were Oshima, Senzhang, Glubinnoe/2004-like strains, and the strain of hemorrhagic form of TBE [Loktev VB et al 2007;Leonova GN & Pavlenko EV, 2009]. Genetic diversity of TBEV was detected, when all three main TBEV genotypes could circulate simultaneously on the same territory [Pogodina VV.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Immunological Efficiency Among Patients Vaccinated Against Tick-Borne Encephalitis

Леонова¹

2011

Flavivirus Encephalitis

View full text Add to dashboard Cite

Ability of inactivated vaccines based on far‐eastern tick‐borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients

Майкова

Chernokhaeva

Rogova

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Tick-borne encephalitis (TBE) remains one of the major public health concerns in northern Eurasia, and its' area is expanding. TBE virus (TBEV) includes three subtypes and several monophyletic groups, cocirculating in Russia. Five inactivated vaccines are used for TBE prophylaxis. The rising number of people subjected to vaccination brings up the issue of the impact of individual recipient characteristics on vaccination efficacy. The present work studies correlations among the vaccination scheme, sex, age, body mass index (BMI), chronic diseases, postvaccinal reaction, pre-existing anti-TBEV antibodies, and postvaccinal humoral immunity development. Sera were collected during clinical trials in the TBEV Siberian subtype endemic area. Adult recipients were vaccinated with Tick-E-Vac and EnceVir vaccines based on Far-Eastern TBEV strains. Vaccine ability to induce humoral immunity in different categories of recipients was estimated by seroconversion rates and the percentage of recipients with high neutralizing antibody titers (≥1:500). High immunogenicity of vaccines based on Far-Eastern TBEV strains in the TBEV Siberian subtype endemic area in all groups of recipients was demonstrated. Impact of pre-existing contact with the virus and high BMI on humoral immune response development 14 days after the first immunization was evidenced. Nevertheless, the difference was significantly less pronounced 30 days after the first vaccination and undetectable after the second one.

show abstract

Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human

Cited by 48 publications

References 11 publications

Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

Evaluation of Immunological Efficiency Among Patients Vaccinated Against Tick-Borne Encephalitis

Ability of inactivated vaccines based on far‐eastern tick‐borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients

Contact Info

Product

Resources

About